Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics

被引:9
|
作者
Yuan, Heng [1 ]
Jung, Eun-Soo [2 ,3 ,4 ]
Chae, Soo-Wan [2 ,3 ,4 ]
Jung, Su-Jin [2 ,3 ,4 ]
Daily, James W. [5 ]
Park, Sunmin [1 ,6 ]
机构
[1] Hoseo Univ, Dept Bioconvergence, Asan 31499, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[3] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[4] Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju 54907, South Korea
[5] Daily Mfg Inc, Dept R&D, Rockwell, NC 28138 USA
[6] Hoseo Univ, Obes Diabet Res Ctr, Dept Food & Nutr, 20 Hoseoro79 Bungil, Asan 31499, South Korea
关键词
metabolic dysfunction-associated steatotic liver disease; HFFs; gut microbiota; omics approach; HEPATIC STEATOSIS; NONCODING RNAS; DISEASE; PATHOGENESIS; CELLS; INFLAMMATION; CROSSTALK; NAFLD; NASH;
D O I
10.3390/nu16183061
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores the potential of health functional foods (HFFs) to maintain healthy liver function and prevent MASLD through an integrative analysis of network pharmacology, gut microbiota, and multi-omics approaches. We first examined the biomarkers associated with MASLD, emphasizing the complex interplay of genetic, environmental, and lifestyle factors. We then applied network pharmacology to identify food components with potential beneficial effects on liver health and metabolic function, elucidating their action mechanisms. This review identifies and evaluates strategies for halting or reversing the development of steatotic liver disease in the early stages, as well as biomarkers that can evaluate the success or failure of such strategies. The crucial role of the gut microbiota and its metabolites for MASLD prevention and metabolic homeostasis is discussed. We also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, and integrated multi-omics analyses, in research on preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms and potential biomarkers for HFF development. The review concludes by proposing an integrated approach for developing HFFs targeting MASLD prevention, considering the Korean regulatory framework. We outline future research directions that bridge the gap between basic science and practical applications in health functional food development. This narrative review provides a foundation for researchers and food industry professionals interested in developing HFFs to support liver health. Emphasis is placed on maintaining metabolic balance and focusing on prevention and early-stage intervention strategies.
引用
收藏
页数:22
相关论文
共 26 条
  • [21] Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review
    Ku, Jie-Lun
    Hsu, Jia-Rou
    Li, Yung-Tsung
    Wu, Li-Ling
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (01) : 33 - 40
  • [22] Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis
    Omana-Guzman, Isabel
    Rosas-Diaz, Marisol
    Martinez-Lopez, Yoscelina Estrella
    Perez-Navarro, L. Monserrat
    Diaz-Badillo, Alvaro
    Alanis, Anthony
    Bustamante, Alejandra
    Castillo-Ruiz, Octelina
    del Toro-Cisneros, Noemi
    Esquivel-Hernandez, Diego Armando
    Garcia-Villalobos, Gloria
    Garibay-Nieto, Nayely
    Garcia-Oropesa, Esperanza Milagros
    Hernandez-Martinez, Juan Carlos
    Lopez-Sosa, Elena Beatriz
    Maldonado, Carlos
    Martinez, David
    Membreno, Joshua
    Moctezuma-Chavez, Oscar Omar
    Munguia-Cisneros, Claudia X.
    Nava-Gonzalez, Edna J.
    Perales-Torres, Adriana L.
    Perez-Garcia, Adolfo
    Rivera-Marrero, Hector
    Valdez, Alisha
    Vazquez-Chavez, Alfonso Alejandro
    Ramirez-Pfeiffer, Carlos
    Carter, Kathleen V.
    Tapia, Beatriz
    Vela, Leonel
    Lopez-Alvarenga, Juan Carlos
    BMC MEDICINE, 2024, 22 (01):
  • [23] Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learning
    Weiliang Zhang
    Weirong Lu
    Yaqi Jiao
    Tianhao Li
    Haining Wang
    Chunhua Wan
    Journal of Translational Medicine, 23 (1)
  • [24] Alpha-aminobutyric acid ameliorates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) progression in mice via enhancing AMPK/SIRT1 pathway and modulating the gut-liver axis
    Felicianna
    Lo, Emily Kwun Kwan
    Chen, Congjia
    Ismaiah, Marsena Jasiel
    Zhang, Fangfei
    Leung, Hoi Kit Matthew
    El-Nezami, Hani
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2025, 140
  • [25] The development of a food-group, tree classification method and its use in exploring dietary associations with metabolic dysfunction-associated Steatotic liver disease (MASLD) and other health-related outcomes in a UK population
    Alawadi, Amina A.
    Vijay, Amrita
    Grove, Jane I.
    Taylor, Moira A.
    Aithal, Guruprasad P.
    METABOLISM OPEN, 2025, 25
  • [26] Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis"
    Ren, Tian-Yi
    Eslam, Mohammed
    Fan, Jian-Gao
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)